Depresija un neirotiski traucējumi pacientiem, kas saņem ārstēšanu plaušu slimību nodaļā
No Thumbnail Available
Date
2023
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Rīgas Stradiņa universitāte
Rīga Stradiņš University
Rīga Stradiņš University
Abstract
Elpošanas sistēmas slimības ir viens no biežākajiem hospitalizācijas iemesliem pasaulē. Pēdējo gadu aktuālāka tēma plaušu slimību pētniecībā ir 2019. gada koronavīrusa slimība (COVID-19). Iepriekš veiktajos pētījumos, augsta depresijas un trauksmes prevalence ir atzīmēta gan stacionētiem pacientiem ar COVID-19, gan pacientiem pēc COVID-19 pārslimošanas. Tomēr pētījumos, kas tika veikti pandēmijās sākumā, COVID-19 pacientu izolācijas dēļ depresijas un trauksmes simptomu netika salīdzināta ar citu plaušu slimību pacientu simptomu prevalenci vienas nodaļas ietvaros. Šī pētījuma mērķis bija izpētīt depresijas un trauksmes simptomu izplatību plaušu slimību nodaļas pacientiem, analizēt saistību starp psihisko simptomu smagumu un leikocītu un iekaisuma marķieru līmeni.
Pētījums tika veikts Paula Stradiņa Klīniskās universitātes slimnīcā Rīgā. Pacienti vecumā no 18 gadiem, kuri varēja parakstīt informētu piekrišanu, bija atlasīti pētījumam. Lai novērtētu depresiju un trauksmi, tika izmantota 9 vienību Pacientu Veselības Aptauja (PHQ-9) un 7 vienību Ģeneralizētas trauksmes skala (GAD-7). Informācija par klīnisko diagnozi un leikocītu, prokalcitonīna, C-reaktīvā olbaltuma līmeni tika iegūta no medicīniskas dokumentācijas.
Tika novērtēts 51 piemērots pacients. 59% (n=30) no dalībniekiem tika novēroti vieglas līdz vidēji smagas depresijas simptomi un 25% (n=13) tika novēroti vieglas līdz smagas trauksmes simptomi. Netika atklāta statistiski nozīmīga atšķirība depresijas (p=0,551) un trauksmes (p=0,630) simptomu izplatībā pacientiem ar COVID-19 un ne-COVID-19 pneimoniju. Tika konstatēta negatīva korelācija (Rs=-0,405, p=0,004) starp leikocītu līmeni un depresijas simptomu smagumu. Netika atklāta statistiski nozīmīga korelācija starp iekaisuma marķieru līmeni un trauksmes vai depresijas simptomiem.
Pētījumā tika noteikta augsta depresijas un trauksmes simptomu prevalence pacientiem plaušu slimību nodaļā. Covid-19 pacientiem depresijas un trauksmes līmenis nav augstāks salīdzinājumā ar citiem pneimonijas pacientiem. Augstāks leikocitu un iekaisuma marķieru līmenis asinīs nav tieši saistīts ar smagākiem trauksmes vai depresijas simptomiem. Papildus novērtējums ir svarīgs plaušu slimību pacientiem, lai novērstu depresiju un trauksmi pēc izrakstīšanas no slimnīcas.
Respiratory diseases are one of the most common causes of hospitalization in the world. Most relevant topic of pulmonary disease research in the last few years is the Coronavirus disease 2019 (COVID-19). In previous studies, high prevalence of depression and anxiety in Covid-19 patients was marked both in hospitalized patients and in patients recovering from COVID-19. However, in studies conducted during the beginning of the pandemic, due to the isolation of Covid-19 patients, depression and anxiety symptom prevalence was not compared to other lung disease patients’ symptom prevalence within one hospital department. The purpose of this study was to explore the prevalence of depressive and anxiety symptoms in patients of pulmonary department, to analyze the connection between the severity of psychiatric symptoms and levels of leukocytes and inflammatory markers. Study was conducted in Pauls Stradiņš Clinical University Hospital in Riga. Patients aged 18 or older, who were able to sign the informed consent were selected to participate. The 9-item Patient Health Questionnaire (PHQ-9) and the 7-item Generalized Anxiety Disorder Scale (GAD-7) were used to assess depression and anxiety. Information on clinical diagnosis and levels of leukocytes, procalcitonin, C-reactive protein was collected from medical records. 51 eligible patients were assessed. 59% (n=30) of participants experienced symptoms of mild to moderately severe depression and 25% (n=13) experienced symptoms of mild to severe anxiety. No statistically significant difference was discovered in depression (p=0.551) and anxiety (p=0.630) symptom prevalence between patients with COVID-19 and non-COVID-19 pneumonia. There was a negative correlation (Rs=-0.405, p=0,004) between the level of leukocytes and severity of depressive symptoms. No significant correlation was discovered between levels of inflammatory markers and anxiety and depressive symptoms. The study identified a high prevalence of depression and anxiety symptoms in patients of the pulmonary department. COVID-19 patients do not experience higher levels of depression and anxiety in comparison to other pneumonia patients. Higher levels of leukocytosis and inflammatory markers are not directly connected to more severe anxiety or depressive symptoms. Additional follow-up assessment is important for pulmonary disease patients in order to prevent depression and anxiety after hospital discharge.
Respiratory diseases are one of the most common causes of hospitalization in the world. Most relevant topic of pulmonary disease research in the last few years is the Coronavirus disease 2019 (COVID-19). In previous studies, high prevalence of depression and anxiety in Covid-19 patients was marked both in hospitalized patients and in patients recovering from COVID-19. However, in studies conducted during the beginning of the pandemic, due to the isolation of Covid-19 patients, depression and anxiety symptom prevalence was not compared to other lung disease patients’ symptom prevalence within one hospital department. The purpose of this study was to explore the prevalence of depressive and anxiety symptoms in patients of pulmonary department, to analyze the connection between the severity of psychiatric symptoms and levels of leukocytes and inflammatory markers. Study was conducted in Pauls Stradiņš Clinical University Hospital in Riga. Patients aged 18 or older, who were able to sign the informed consent were selected to participate. The 9-item Patient Health Questionnaire (PHQ-9) and the 7-item Generalized Anxiety Disorder Scale (GAD-7) were used to assess depression and anxiety. Information on clinical diagnosis and levels of leukocytes, procalcitonin, C-reactive protein was collected from medical records. 51 eligible patients were assessed. 59% (n=30) of participants experienced symptoms of mild to moderately severe depression and 25% (n=13) experienced symptoms of mild to severe anxiety. No statistically significant difference was discovered in depression (p=0.551) and anxiety (p=0.630) symptom prevalence between patients with COVID-19 and non-COVID-19 pneumonia. There was a negative correlation (Rs=-0.405, p=0,004) between the level of leukocytes and severity of depressive symptoms. No significant correlation was discovered between levels of inflammatory markers and anxiety and depressive symptoms. The study identified a high prevalence of depression and anxiety symptoms in patients of the pulmonary department. COVID-19 patients do not experience higher levels of depression and anxiety in comparison to other pneumonia patients. Higher levels of leukocytosis and inflammatory markers are not directly connected to more severe anxiety or depressive symptoms. Additional follow-up assessment is important for pulmonary disease patients in order to prevent depression and anxiety after hospital discharge.
Description
Medicīna
Medicine
Veselības aprūpe
Health Care
Medicine
Veselības aprūpe
Health Care
Keywords
depresija; trauksme; plaušu slimības; COVID-19; pneimonija; leikocitoze; C-reaktīvais olbaltums; prokalcitonīns; plaušu slimību nodaļa, depression; anxiety; lung disease; COVID-19; pneumonia; leukocytosis; C-reactive protein; procalcitonin; pulmonary department